148 related articles for article (PubMed ID: 32912440)
1. New cannabinoid receptor antagonists as pharmacological tool.
González-Naranjo P; Pérez C; Girón R; Sánchez-Robles EM; Martín-Fontelles MI; Carrillo-López N; Martín-Vírgala J; Naves M; Campillo NE; Páez JA
Bioorg Med Chem; 2020 Oct; 28(19):115672. PubMed ID: 32912440
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products.
An D; Peigneur S; Hendrickx LA; Tytgat J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32709050
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
Banister SD; Moir M; Stuart J; Kevin RC; Wood KE; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Glass M; Connor M; McGregor IS; Kassiou M
ACS Chem Neurosci; 2015 Sep; 6(9):1546-59. PubMed ID: 26134475
[TBL] [Abstract][Full Text] [Related]
6. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD
Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091
[TBL] [Abstract][Full Text] [Related]
8. Indazolylketones as new multitarget cannabinoid drugs.
González-Naranjo P; Pérez-Macias N; Pérez C; Roca C; Vaca G; Girón R; Sánchez-Robles E; Martín-Fontelles MI; de Ceballos ML; Martin-Requero A; Campillo NE; Páez JA
Eur J Med Chem; 2019 Mar; 166():90-107. PubMed ID: 30685536
[TBL] [Abstract][Full Text] [Related]
9. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
Nimczick M; Decker M
ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA.
Longworth M; Connor M; Banister SD; Kassiou M
ACS Chem Neurosci; 2017 Aug; 8(8):1673-1680. PubMed ID: 28574245
[TBL] [Abstract][Full Text] [Related]
11. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors.
Noble C; Cannaert A; Linnet K; Stove CP
Drug Test Anal; 2019 Mar; 11(3):501-511. PubMed ID: 30280499
[TBL] [Abstract][Full Text] [Related]
12. Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors.
Murineddu G; Ruiu S; Mussinu JM; Loriga G; Grella GE; Carai MA; Lazzari P; Pani L; Pinna GA
Bioorg Med Chem; 2005 May; 13(9):3309-20. PubMed ID: 15809166
[TBL] [Abstract][Full Text] [Related]
13. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
14. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
Canazza I; Ossato A; Trapella C; Fantinati A; De Luca MA; Margiani G; Vincenzi F; Rimondo C; Di Rosa F; Gregori A; Varani K; Borea PA; Serpelloni G; Marti M
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3685-3709. PubMed ID: 27527584
[TBL] [Abstract][Full Text] [Related]
15. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
16. The development of cannabinoid antagonists.
Barth F; Rinaldi-Carmona M
Curr Med Chem; 1999 Aug; 6(8):745-55. PubMed ID: 10469889
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
18. CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.
Flavin A; Azizi P; Murataeva N; Yust K; Du W; Ross R; Greig I; Nguyen T; Zhang Y; Mackie K; Straiker A
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675703
[TBL] [Abstract][Full Text] [Related]
19. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
